The cancer therapeutics landscape is constantly evolving as breakthroughs across modalities drive toward the shared goal of providing accessible and life-saving treatments to patients. Companies are addressing the urgent unmet needs of patients with targeted therapies tailored to patients’ specific cancer profile and improving quality of life while undergoing treatment with therapies that have better efficacy and fewer side effects. Despite setbacks, we are witnessing differentiated and innovative approaches designed to address both common and rare cancers. This panel of thought leaders will investigate the latest breakthroughs in oncology, offering a comparative analysis of these advancements, from next-generation ADCs to cutting-edge in vivo immunotherapies and combination approaches, while examining the potential these modalities hold to outsmart the disease at its core.